Fundraising Fox
Janux Therapeutics
La Jolla, US · Founded 2017 · 122 employees on LinkedIn · 3 known investors
Find your way into Janux Therapeutics
Sign up to see every warm intro you have to Janux Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Janux Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Janux Therapeutics is a clinical-stage biotech company developing precision-engineered immunotherapies for the treatment of cancer and autoimmune diseases. It uses its TRACTr, TRACIr, and ARM platforms to engineer drug candidates intended to direct the immune system against disease while limiting systemic safety issues.
Founders & leadership
Board
Investors · 3
How we know: Avalon BioVentures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: OrbiMed's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$192.4M disclosed across 3 rounds · 2020–2021
▶$125MraisedApr 2021 · 22 investors · BiotechnologyRule 506(b)
- Jay Lichter, Ph.D.Director
- Jake Simson, Ph.D.Director
- Stefan HellerDirector
- Peter Thompson, M.D.Director
- Vickie L. CappsDirector
- David Campbell, Ph.D.Executive Officer, Director
- Sheila GujrathiDirector
- Tighe ReardonExecutive Officer
- Offering amount
- $125M
- Amount sold
- $125M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$56MraisedMar 2021 · 7 investors · BiotechnologyRule 506(b)
- Jay Lichter, Ph.D.Director
- Jake Simson, Ph.D.Director
- Tighe ReardonExecutive Officer
- Stefan HellerDirector
- Peter Thompson, M.D.Director
- David Campbell, Ph.D.Executive Officer, Director
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$11.4MraisedJul 2020 · 3 investors · BiotechnologyRule 506(b)
- Jay Lichter, Ph.D.Director
- Stefan HellerDirector
- Tighe ReardonExecutive Officer
- David Campbell, Ph.D.Executive Officer, Director
- Offering amount
- $15.9M
- Amount sold
- $11.4M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Janux Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Janux Therapeutics do?
- Janux Therapeutics is a clinical-stage biotech company developing precision-engineered immunotherapies for the treatment of cancer and autoimmune diseases. It uses its TRACTr, TRACIr, and ARM platforms to engineer drug candidates intended to direct the immune system against disease while limiting systemic safety issues.
- Who are Janux Therapeutics's investors?
- Janux Therapeutics's investors include Avalon BioVentures, OrbiMed, Samsara BioCapital.
- How much funding has Janux Therapeutics raised?
- Janux Therapeutics has disclosed $192.4M raised across 3 rounds.
- Where is Janux Therapeutics headquartered?
- Janux Therapeutics is headquartered in La Jolla, US.